Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
amoxicillin, vattenfritt (som amoxicillin) 200 milligram och klavulansyra (som kaliumklavulanat) 28,5 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin, vattenfritt (som amoxicillin) 200 milligram och klavulansyra (som kaliumklavulanat) 28,5 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amoxicillin, vattenfritt (som amoxicillin) 200 milligram och klavulansyra (som kaliumklavulanat) 28,5 milligram, tuggtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
doxycyklinmonohydrat 100 milligram, munsönderfallande tablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
doxycyklinmonohydrat 100 milligram, munsönderfallande tablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin, vattenfritt (som amoxicillin) 775 milligram, depåtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
amoxicillin, vattenfritt (som amoxicillin) 775 milligram, depåtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin, vattenfritt (som amoxicillin) 250 milligram och klavulansyra (som kaliumklavulanat) 62,5 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin, vattenfritt (som amoxicillin) 250 milligram och klavulansyra (som kaliumklavulanat) 62,5 milligram, tuggtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
amoxicillin, vattenfritt (som amoxicillin) 250 milligram och klavulansyra (som kaliumklavulanat) 62,5 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
amoxicillin, vattenfritt (som amoxicillin) 250 milligram, tuggtablett |
Has presentation strength denominator unit (attribute) |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
amoxicillin, vattenfritt (som amoxicillin) 250 milligram, tuggtablett |
Has unit of presentation |
False |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely clarithromycin 1 gram/1 each prolonged-release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely clarithromycin 1 gram/1 each prolonged-release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Lanthanum (as lanthanum carbonate) 1 g chewable tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Lanthanum (as lanthanum carbonate) 1 g chewable tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Mycophenolic acid (as mycophenolate sodium) 180 mg gastro-resistant oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Deferasirox 250 mg tablet for oral suspension |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Deferasirox 250 mg tablet for oral suspension |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely deferasirox 125 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely deferasirox 125 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely deferasirox 500 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely deferasirox 500 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely magnesium aspartate 615 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely magnesium aspartate 615 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Mycophenolic acid (as mycophenolate sodium) 180 mg gastro-resistant oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Venetoclax 10 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Venetoclax 10 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Venetoclax 50 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Venetoclax 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Venetoclax 100 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Venetoclax 100 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely ivosidenib 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely ivosidenib 250 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Alpelisib 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Alpelisib 50 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely alpelisib 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely alpelisib 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely alpelisib 200 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely alpelisib 200 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely apremilast 20 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely apremilast 20 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Apremilast 10 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Apremilast 10 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely apremilast 30 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely apremilast 30 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely pirfenidone 267 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely pirfenidone 267 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely pirfenidone 801 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely pirfenidone 801 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Lasmiditan 50 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Lasmiditan 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely osilodrostat (as osilodrostat phosphate) 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely osilodrostat (as osilodrostat phosphate) 1 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely osilodrostat (as osilodrostat phosphate) 5 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely osilodrostat (as osilodrostat phosphate) 5 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Osilodrostat (as osilodrostat phosphate) 10 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Osilodrostat (as osilodrostat phosphate) 10 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Bempedoic acid 180 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Bempedoic acid 180 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bempedoic acid 180 milligram and ezetimibe 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely bempedoic acid 180 milligram and ezetimibe 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely bempedoic acid 180 milligram and ezetimibe 10 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Pemigatinib 4.5 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Pemigatinib 4.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Pemigatinib 9 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Pemigatinib 9 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Pemigatinib 13.5 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Pemigatinib 13.5 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Tucatinib 50 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Tucatinib 50 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely tucatinib 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely tucatinib 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Olaparib 150 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Olaparib 150 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely olaparib 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely olaparib 100 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Nevirapine 50 mg prolonged-release oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Nevirapine 50 mg prolonged-release oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Abacavir (as abacavir sulfate) 60 mg dispersible oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Abacavir (as abacavir sulfate) 60 mg dispersible oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely efavirenz 600 milligram and lamivudine 300 milligram and tenofovir disoproxil fumarate 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely efavirenz 600 milligram and lamivudine 300 milligram and tenofovir disoproxil fumarate 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely efavirenz 600 milligram and lamivudine 300 milligram and tenofovir disoproxil fumarate 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely efavirenz 600 milligram and lamivudine 300 milligram and tenofovir disoproxil fumarate 300 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
3 |
Product containing precisely tenofovir disoproxil fumarate 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely tenofovir disoproxil fumarate 150 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Capmatinib 200 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Capmatinib 200 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Capmatinib 150 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Capmatinib 150 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Product containing precisely ripretinib 50 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely ripretinib 50 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Atazanavir (as atazanavir sulfate) 300 mg and ritonavir 100 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Atazanavir (as atazanavir sulfate) 300 mg and ritonavir 100 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Atazanavir (as atazanavir sulfate) 300 mg and ritonavir 100 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
2 |
Product containing precisely pyridoxine hydrochloride 40 milligram/1 each conventional release oral tablet (clinical drug) |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Product containing precisely pyridoxine hydrochloride 40 milligram/1 each conventional release oral tablet (clinical drug) |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Pyrazinamide 400 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|
Pyrazinamide 400 mg oral tablet |
Has presentation strength denominator unit (attribute) |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
1 |
Ethambutol hydrochloride 275 mg and isoniazid 75 mg and rifampicin 150 mg oral tablet |
Has unit of presentation |
True |
Tablet (unit of presentation) |
Inferred relationship |
Some |
|